Potential biomarkers for vascular damage in ALzheimer’s disease: Thrombomodulin and von Willebrand factor
Objectives Evidence regarding the vascular basis of Alzheimer’s disease (AD) is growing. In vascular damage thrombomodulin tears of the cell wall and its level increases in the plasma. von Willebrand factor (vWF) is also thought to be a biomarker for vascular damage. The aim of this study was to exa...
Gespeichert in:
Veröffentlicht in: | The Journal of nutrition, health & aging health & aging, 2010-06, Vol.14 (6), p.439-441 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objectives
Evidence regarding the vascular basis of Alzheimer’s disease (AD) is growing. In vascular damage thrombomodulin tears of the cell wall and its level increases in the plasma. von Willebrand factor (vWF) is also thought to be a biomarker for vascular damage. The aim of this study was to examine the levels of vWF and thrombomodulin in AD as possible markers for vascular damage and to test their utility as an early biomarker in AD.
Design
Case-control study.
Setting
Geriatric medicine outpatient clinic of a university hospital.
Participants
Twenty Alzheimer’s disease patients free from vascular risk factors and 20 controls were enrolled in the study.
Measurements
Thrombomodulin and VWF levels of 20 AD patients and 20 controls were analyzed by commercial kits.
Results
Thrombomodulin levels were not different between Alzheimer’s disease and control groups [median (range) = 4.25 (2.27–37.00) ng/ml in Alzheimer’s disease and 3.55 (2.27–14.00) in control group, p=0.15]. Von Willebrand Factor antigen (%) levels were 188.5 (96–306) in Alzheimer’s disease, and 181 (112–284) in control group (p=0.74).
Conclusion
Although vascular damage is thought to play role in the pathogenesis of AD, vWF and thrombomodulin failed to demonstrate the vascular damage in AD. Their utility to be used as early biomarkers of AD could not be shown. |
---|---|
ISSN: | 1279-7707 1760-4788 |
DOI: | 10.1007/s12603-010-0043-8 |